{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T22:10:22Z","timestamp":1784153422909,"version":"3.55.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,11,9]],"date-time":"2018-11-09T00:00:00Z","timestamp":1541721600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs Aging"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1007\/s40266-018-0609-4","type":"journal-article","created":{"date-parts":[[2018,11,8]],"date-time":"2018-11-08T20:44:54Z","timestamp":1541709894000},"page":"65-71","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Serum Concentrations and Elimination Rates of Direct-Acting Oral Anticoagulants (DOACs) in Older Hip Fracture Patients Hospitalized for Surgery: A Pilot Study"],"prefix":"10.1007","volume":"36","author":[{"given":"Kirsten K.","family":"Viktil","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ina","family":"Lehre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anette H.","family":"Ranhoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6190-2751","authenticated-orcid":false,"given":"Espen","family":"Molden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,11,9]]},"reference":[{"key":"609_CR1","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","volume":"361","author":"SJ Connolly","year":"2009","unstructured":"Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139\u201351.","journal-title":"N Engl J Med"},{"key":"609_CR2","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","volume":"369","author":"RP Giugliano","year":"2013","unstructured":"Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, Waldo AL, Ezekowitz MD, Weitz JI, Spinar J, Ruzyllo W, Ruda M, Koretsune Y, Betcher J, Shi M, Grip LT, Patel SP, Patel I, Hanyok JJ, Mercuri M, Antman EM. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369:2093\u2013104.","journal-title":"N Engl J Med"},{"key":"609_CR3","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1056\/NEJMoa1107039","volume":"365","author":"CB Granger","year":"2011","unstructured":"Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, Al-Khalidi HR, Ansell J, Atar D, Avezum A, Bahit MC, Diaz R, Easton JD, Ezekowitz JA, Flaker G, Garcia D, Geraldes M, Gersh BJ, Golitsyn S, Goto S, Hermosillo AG, Hohnloser SH, Horowitz J, Mohan P, Jansky P, Lewis BS, Lopez-Sendon JL, Pais P, Parkhomenko A, Verheugt FW, Zhu J, Wallentin L. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981\u201392.","journal-title":"N Engl J Med"},{"key":"609_CR4","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1056\/NEJMoa1009638","volume":"365","author":"MR Patel","year":"2011","unstructured":"Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Piccini JP, Becker RC, Nessel CC, Paolini JF, Berkowitz SD, Fox KA, Califf RM. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883\u201391.","journal-title":"N Engl J Med"},{"key":"609_CR5","first-page":"718","volume":"13","author":"N Karamichalakis","year":"2016","unstructured":"Karamichalakis N, Georgopoulos S, Vlachos K, Liatakis I, Efremidis M, Sideris A, Letsas KP. Efficacy and safety of novel anticoagulants in the elderly. J Geriatr Cardiol. 2016;13:718\u201323.","journal-title":"J Geriatr Cardiol"},{"key":"609_CR6","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1007\/s40266-013-0119-3","volume":"30","author":"C Stollberger","year":"2013","unstructured":"Stollberger C, Finsterer J. Concerns about the use of new oral anticoagulants for stroke prevention in elderly patients with atrial fibrillation. Drugs Aging. 2013;30:949\u201358.","journal-title":"Drugs Aging"},{"key":"609_CR7","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s40266-016-0363-4","volume":"33","author":"C Stollberger","year":"2016","unstructured":"Stollberger C, Brooks R, Finsterer J, Pachofszky T. Use of direct-acting oral anticoagulants in nonagenarians: a call for more data. Drugs Aging. 2016;33:315\u201320.","journal-title":"Drugs Aging"},{"key":"609_CR8","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1111\/j.1532-5415.2009.02377.x","volume":"57","author":"V Juliebo","year":"2009","unstructured":"Juliebo V, Bjoro K, Krogseth M, Skovlund E, Ranhoff AH, Wyller TB. Risk factors for preoperative and postoperative delirium in elderly patients with hip fracture. J Am Geriatr Soc. 2009;57:1354\u201361.","journal-title":"J Am Geriatr Soc"},{"key":"609_CR9","doi-asserted-by":"crossref","unstructured":"Moja L, Piatti A, Pecoraro V, Ricci C, Virgili G, Salanti G, Germagnoli L, Liberati A, Banfi G. Timing matters in hip fracture surgery: patients operated within 48 hours have better outcomes. A meta-analysis and meta-regression of over 190,000 patients. PLoS One 2012;7:e46175.","DOI":"10.1371\/journal.pone.0046175"},{"key":"609_CR10","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1503\/cmaj.092220","volume":"182","author":"N Simunovic","year":"2010","unstructured":"Simunovic N, Devereaux PJ, Sprague S, Guyatt GH, Schemitsch E, Debeer J, Bhandari M. Effect of early surgery after hip fracture on mortality and complications: systematic review and meta-analysis. CMAJ. 2010;182:1609\u201316.","journal-title":"CMAJ"},{"key":"609_CR11","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1302\/2058-5241.1.160034","volume":"1","author":"I Ktistakis","year":"2016","unstructured":"Ktistakis I, Giannoudis V, Giannoudis PV. Anticoagulation therapy and proximal femoral fracture treatment: an update. EFORT Open Rev. 2016;1:310\u20135.","journal-title":"EFORT Open Rev"},{"key":"609_CR12","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1302\/2058-5241.2.160083","volume":"2","author":"R Yassa","year":"2017","unstructured":"Yassa R, Khalfaoui MY, Hujazi I, Sevenoaks H, Dunkow P. Management of anticoagulation in hip fractures: a pragmatic approach. EFORT Open Rev. 2017;2:394\u2013402.","journal-title":"EFORT Open Rev"},{"key":"609_CR13","unstructured":"(EMA) RXpiabtEMA. Available at: \n                    http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/medicines\/000944\/human_med_001155.jsp&mid=WC0b01ac058001d124\n                    \n                  ."},{"key":"609_CR14","unstructured":"(EMA). AEpiabtEMA. Available at: \n                    http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/medicines\/002148\/human_med_001449.jsp&mid=WC0b01ac058001d124\n                    \n                  ."},{"key":"609_CR15","unstructured":"(EMA). DPpiabtEMA. Available at: \n                    http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/medicines\/000829\/human_med_000981.jsp&mid=WC0b01ac058001d124\n                    \n                  ."},{"key":"609_CR16","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1111\/j.1365-2753.2006.00753.x","volume":"13","author":"C Scullin","year":"2007","unstructured":"Scullin C, Scott MG, Hogg A, McElnay JC. An innovative approach to integrated medicines management. J Eval Clin Pract. 2007;13:781\u20138.","journal-title":"J Eval Clin Pract"},{"key":"609_CR17","doi-asserted-by":"publisher","first-page":"899","DOI":"10.2215\/CJN.05371008","volume":"4","author":"R Botev","year":"2009","unstructured":"Botev R, Mallie JP, Couchoud C, Schuck O, Fauvel JP, Wetzels JF, Lee N, De Santo NG, Cirillo M. Estimating glomerular filtration rate: Cockcroft-Gault and Modification of Diet in Renal Disease formulas compared to renal inulin clearance. Clin J Am Soc Nephrol. 2009;4:899\u2013906.","journal-title":"Clin J Am Soc Nephrol"},{"key":"609_CR18","doi-asserted-by":"crossref","unstructured":"Lundgaard H, Dyrkorn R, Stokes CL, Molden E, Spigset O. Safer treatment with serum concentration monitoring of the new anticoagulants? Tidsskr Nor Laegeforen. 2016;136:1556\u201360 (Readers may contact the authors for an English translation of key points in the paper).","DOI":"10.4045\/tidsskr.16.0255"},{"key":"609_CR19","doi-asserted-by":"publisher","first-page":"g4670","DOI":"10.1136\/bmj.g4670","volume":"349","author":"D Cohen","year":"2014","unstructured":"Cohen D. Dabigatran: how the drug company withheld important analyses. BMJ. 2014;349:g4670.","journal-title":"BMJ"},{"key":"609_CR20","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.jacc.2013.07.104","volume":"63","author":"PA Reilly","year":"2014","unstructured":"Reilly PA, Lehr T, Haertter S, Connolly SJ, Yusuf S, Eikelboom JW, Ezekowitz MD, Nehmiz G, Wang S, Wallentin L. The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY trial (Randomized Evaluation of Long-Term Anticoagulation Therapy). J Am Coll Cardiol. 2014;63:321\u20138.","journal-title":"J Am Coll Cardiol"},{"key":"609_CR21","doi-asserted-by":"publisher","first-page":"S24","DOI":"10.1016\/j.cjca.2013.04.002","volume":"29","author":"IY Gong","year":"2013","unstructured":"Gong IY, Kim RB. Importance of pharmacokinetic profile and variability as determinants of dose and response to dabigatran, rivaroxaban, and apixaban. Can J Cardiol. 2013;29:S24\u201333.","journal-title":"Can J Cardiol"},{"key":"609_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40262-013-0100-7","volume":"53","author":"W Mueck","year":"2014","unstructured":"Mueck W, Stampfuss J, Kubitza D, Becka M. Clinical pharmacokinetic and pharmacodynamic profile of rivaroxaban. Clin Pharmacokinet. 2014;53:1\u201316.","journal-title":"Clin Pharmacokinet"},{"key":"609_CR23","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.thromres.2015.04.030","volume":"136","author":"M Skeppholm","year":"2015","unstructured":"Skeppholm M, Al-Aieshy F, Berndtsson M, Al-Khalili F, Ronquist-Nii Y, Soderblom L, Ostlund AY, Pohanka A, Antovic J, Malmstrom RE. Clinical evaluation of laboratory methods to monitor apixaban treatment in patients with atrial fibrillation. Thromb Res. 2015;136:148\u201353.","journal-title":"Thromb Res"},{"key":"609_CR24","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1056\/NEJMoa1607887","volume":"375","author":"SJ Connolly","year":"2016","unstructured":"Connolly SJ, Milling TJ Jr, Eikelboom JW, Gibson CM, Curnutte JT, Gold A, Bronson MD, Lu G, Conley PB, Verhamme P, Schmidt J, Middeldorp S, Cohen AT, Beyer-Westendorf J, Albaladejo P, Lopez-Sendon J, Goodman S, Leeds J, Wiens BL, Siegal DM, Zotova E, Meeks B, Nakamya J, Lim WT, Crowther M. Andexanet alfa for acute major bleeding associated with factor Xa inhibitors. N Engl J Med. 2016;375:1131\u201341.","journal-title":"N Engl J Med"},{"key":"609_CR25","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1056\/NEJMoa1707278","volume":"377","author":"CV Pollack Jr","year":"2017","unstructured":"Pollack CV Jr, Reilly PA, van Ryn J, Eikelboom JW, Glund S, Bernstein RA, Dubiel R, Huisman MV, Hylek EM, Kam CW, Kamphuisen PW, Kreuzer J, Levy JH, Royle G, Sellke FW, Stangier J, Steiner T, Verhamme P, Wang B, Young L, Weitz JI. Idarucizumab for dabigatran reversal - full cohort analysis. N Engl J Med. 2017;377:431\u201341.","journal-title":"N Engl J Med"},{"key":"609_CR26","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1007\/s40266-017-0476-4","volume":"34","author":"AM Urbaniak","year":"2017","unstructured":"Urbaniak AM, Strom BO, Krontveit R, Svanqvist KH. Prescription patterns of non-vitamin K oral anticoagulants across indications and factors associated with their increased prescribing in atrial fibrillation between 2012\u20132015: a study from the Norwegian Prescription Database. Drugs Aging. 2017;34:635\u201345.","journal-title":"Drugs Aging"},{"key":"609_CR27","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1111\/j.1365-2125.2012.04453.x","volume":"75","author":"S Hartter","year":"2013","unstructured":"Hartter S, Sennewald R, Nehmiz G, Reilly P. Oral bioavailability of dabigatran etexilate (Pradaxa((R))) after co-medication with verapamil in healthy subjects. Br J Clin Pharmacol. 2013;75:1053\u201362.","journal-title":"Br J Clin Pharmacol"},{"key":"609_CR28","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/S0009-9236(98)90030-3","volume":"64","author":"H Wakasugi","year":"1998","unstructured":"Wakasugi H, Yano I, Ito T, Hashida T, Futami T, Nohara R, Sasayama S, Inui K. Effect of clarithromycin on renal excretion of digoxin: interaction with P-glycoprotein. Clin Pharmacol Ther. 1998;64:123\u20138.","journal-title":"Clin Pharmacol Ther"},{"key":"609_CR29","unstructured":"Gupta S. P-glycoprotein expression and regulation. Age-related changes and potential effects on drug therapy. Drugs Aging. 1995;7:19\u201329."},{"key":"609_CR30","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/j.clpt.2006.02.004","volume":"79","author":"R Toornvliet","year":"2006","unstructured":"Toornvliet R, van Berckel BN, Luurtsema G, Lubberink M, Geldof AA, Bosch TM, Oerlemans R, Lammertsma AA, Franssen EJ. Effect of age on functional P-glycoprotein in the blood-brain barrier measured by use of (R)-[(11)C]verapamil and positron emission tomography. Clin Pharmacol Ther. 2006;79:540\u20138.","journal-title":"Clin Pharmacol Ther"}],"container-title":["Drugs & Aging"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40266-018-0609-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-018-0609-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-018-0609-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,8]],"date-time":"2019-11-08T19:27:38Z","timestamp":1573241258000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40266-018-0609-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,9]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["609"],"URL":"https:\/\/doi.org\/10.1007\/s40266-018-0609-4","relation":{},"ISSN":["1170-229X","1179-1969"],"issn-type":[{"value":"1170-229X","type":"print"},{"value":"1179-1969","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,9]]},"assertion":[{"value":"9 November 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"No external funding was used in the preparation of this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Authors KKV, IL, AHR and EM declare that they have no conflicts of interest that might be relevant to the contents of this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}